20.48 USD
-0.29 (-1.4%)
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. These ratings would make PCRX suitable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
- PCRX has a better Return On Assets (1.65%) than 81.15% of its industry peers.
- PCRX has a Return On Equity of 2.95%. This is amongst the best in the industry. PCRX outperforms 82.20% of its industry peers.
- With an excellent Return On Invested Capital value of 3.63%, PCRX belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
- PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- PCRX has a Profit Margin of 2.99%. This is in the better half of the industry: PCRX outperforms 79.58% of its industry peers.
- The Operating Margin of PCRX (8.88%) is better than 81.15% of its industry peers.
- In the last couple of years the Operating Margin of PCRX has grown nicely.
- PCRX has a better Gross Margin (79.17%) than 84.29% of its industry peers.
- PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- Compared to 5 years ago, PCRX has more shares outstanding
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.86. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 1.86, PCRX perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
- PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
- The Debt to FCF ratio of PCRX (3.03) is better than 90.58% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- The Debt to Equity ratio of PCRX (0.52) is worse than 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.86 |
ROIC/WACC0.46
WACC7.9%
2.3 Liquidity
- A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a better Current ratio (5.26) than 64.92% of its industry peers.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX's Quick ratio of 3.78 is fine compared to the rest of the industry. PCRX outperforms 60.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.01% yearly.
- Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 6.38% on average per year.
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 6.90, which indicates a rather cheap valuation of PCRX.
- 93.72% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.30. PCRX is valued rather cheaply when compared to this.
- A Price/Forward Earnings ratio of 5.85 indicates a rather cheap valuation of PCRX.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 93.72% of the companies listed in the same industry.
- PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.9 | ||
| Fwd PE | 5.85 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaply inside the industry as 96.34% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.09 | ||
| EV/EBITDA | 5.99 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.49
EPS Next 2Y4.39%
EPS Next 3Y6.17%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.9 and the Price/Book (PB) ratio is 1.21.